Fecal microbiota transplantation as a therapeutic option for ulcerative colitis

Abstract

Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic option for various gastrointestinal diseases, including ulcerative colitis (UC). This review explores the role of FMT in the management of UC, its mechanisms, efficacy, safety, and limitations. Current research demonstrates that alterations in gut microbiota play a significant role in UC pathogenesis, and FMT can potentially restore microbial balance, reducing inflammation and promoting mucosal healing. However, challenges such as donor selection, standardization of procedures, and patient variability remain. Further research is needed to optimize protocols and ensure long-term efficacy.